CSF3 and lymphoma: 18–60, LDH not elevated, >60 years all risk groups) with newly diagnosed aggressive lymphoma received 6 cycles of CIVEP-14 with an escalating dose of idarubicin, consisting of idarubicin (11–16 mg/m2 d1) and standard doses of cyclophosphamide, vincristine, etoposide, and prednisone with G-CSF support.